Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive dyskinesia.
Tardive dyskinesia (TD) is an abnormal involuntary movement disorder that arises as a common adverse effect in patients using antipsychotic medications, occurring in an estimated 20% of this population. This condition inflicts a substantial negative impact on patient quality of life and clinical outcomes and contributes to the significant rate of nonadherence to antipsychotic medication regimens.
Tardive Dyskinesia 360 is a resource center built for mental health practitioners, designed to educate providers on the proper screening, diagnosis, and treatment of TD. Explore expert video commentary, patient cases activities, instructional videos, and stay up to date on the latest information related to TD care.
From normal (0) to severe (4), see what real tardive dyskinesia movements look like so you can better assess your patients.
Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.
The US Food and Drug Administration has approved deutetrabenazine for the treatment of tardive dyskinesia in adults, Teva Pharmaceutical Industries announced.
In this new, occasional feature, members of the Psych Congress Steering Committee answer questions asked by audience members at Psych Congress meetings. In this installment, cochair Rakesh Jain, MD, MPH, discusses using tardive dyskinesia treatments in conjunction with antipsychotics.
A selective vesicular monoamine transporter 2 (VMAT2) inhibitor can improve symptoms of moderate to severe tardive dyskinesia (TD), posters presented at Psych Congress suggest.